==== Front Pediatr Res Pediatr Res Pediatric Research 0031-3998 1530-0447 Nature Publishing Group US New York 36774398 2513 10.1038/s41390-023-02513-5 Clinical Research Article Brain-derived neurotrophic factor and neuroimaging in pediatric patients with sickle cell disease Mahmoud Asmaa A. asmaasoliman50@gmail.com 1 Abd El Naby Sameh A. 1 Abdelgawad Ahmed S. 2 Rizq Marwa Sabry 3 Abd El Hady Nahla M. S. 1 1 grid.411775.1 0000 0004 0621 4712 Department of Pediatrics—Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt 2 grid.411775.1 0000 0004 0621 4712 Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin Elkom, Egypt 3 grid.411775.1 0000 0004 0621 4712 Department of Pediatrics, National Liver Institute, Menoufia University, Shebin Elkom, Egypt 11 2 2023 11 2 2023 2023 93 7 19221926 2 1 2023 13 1 2023 20 1 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Background The risk of neurological complications is increased in children with sickle cell disease (SCD), such as silent cerebral infarction (SCI) and stroke. Brain-Derived Neurotrophic Factor (BDNF) is a nerve growth factor associated with elevated transcranial Doppler (TCD) velocities and increased risk of stroke in SCD patients. So, we assessed the BDNF level in children with SCD and its relation to neurological complication as silent stroke. Methods A comparative cross-sectional study was conducted on 40 patients with SCD, recruited from the Hematology Unit, Pediatric Department, Menoufia University Hospital, and 40 healthy children as controls. Laboratory investigations including BDNF were done. TCD was done for all patients and Magnetic Resonance Imaging (MRI) was done on high-risk patients. Results BDNF levels were significantly higher in children with SCD than in controls with a significant relation to TCD findings. There was a statistically significant diagnostic ability of BDNF in the prediction of SCD complications as its sensitivity was 89.5%, specificity (95% CI) was 80% with a cut-off point >0.69, AUC = 0.702, and p = 0.004). Conclusion Serum BDNF levels were higher in sickle disease patients who had abnormal transcranial Doppler. BDNF had a significant diagnostic ability in the detection of SCD complications. Impact Silent stroke is a very serious complication in children with sickle cell disease, so regular follow up should be every six months. BDNF is considered a potential biomarker for stroke risk prediction in patients unable to receive TCD. issue-copyright-statement© International Pediatric Research Foundation, Inc 2023 ==== Body pmcIntroduction SCD is caused by a single base pair mutation (Glu6Val) in the β globin gene. The most common genotype is homozygous hemoglobin SS (HbSS), and common heterozygous condition is Sβ0-thalassemia.1 Neurological complications such as silent cerebral infarctions (SCI), overt hemorrhagic and ischemic stroke are increased in the pediatric SCD population.2 Repeated vaso-occlusion in sickle cell anemia (SCA) results in acute pain and end-organ ischemic injury such as stroke.3 In SCA, ischemic stroke incidence is four times higher in children 2–15 years old4 Children with SCA may also develop SCI, without overt stroke.5 Neurotrophins play a pivotal role in the development, functioning, survival, and plasticity of the nervous system. BDNF is a widely distributed neurotrophin in the mammalian CNS; its purification has an important role in mammalian brain development, physiology, and pathology.6 BDNF is thought to participate by inhibiting apoptosis and stimulating sprouting and neuronal reorganization. The cellular actions of BDNF were mediated through tyrosine kinase receptor B (TrkB) and by p75NTR (p75 neurotrophin receptor), a member of the tumor necrosis factor receptor superfamily.7 BDNF has been associated with neuroprotection in ischemic brain injury so, it has prognostic and diagnostic prediction of brain injury.8,9 Methods Study design This comparative cross-sectional study included 40 patients with SCD (they were 22 patients with HbSS and 18 patients with Sβ0-thalassemia diagnosed by hemoglobin electrophoresis) recruited from the hematology unit, pediatric department, Faculty of Medicine, Menoufia University, and 40 healthy volunteers as a control group during the period from April 2021 to April 2022. Patients with other hemoglobinoapathies and other chronic hemolytic anemia were excluded. Informed written consent was obtained from the guardian of all participants. The Institutional Review Board (IRB) of the Menoufia Faculty of Medicine approved the study (ID: 10/2020 PEDI 12). All participants were subjected to complete history taking and physical and clinical examination and laboratory investigations including complete blood count, serum ferritin and BDNF. All SCD patients were on hydroxyurea therapy with good compliance. Sample collection Blood samples of 10 ml were withdrawn from participants during their admission to the hospital by vaso-occlusive crisis under complete aseptic conditions and then were divided into appropriate vacutainer tubes as follows: Two EDTA tubes each contained 2 mL of whole blood for CBC and hemoglobin electrophoresis. Two plain vacutainer tubes each contained 3 mL of blood that was used for serum separation into aliquots to be assayed later for biochemical investigations and BDNF serum level assay. Serum ferritin was measured according to the electro-chemiluminescence immunoassay “ECLIA” procedure by Cobas 6000 (e 601 modules). CBC was done using a cell counter, Sysmex XT1800i Automated Hematology Analyzer. BDNF serum levels were assayed using a double-antibody sandwich ELISA Kit (by SunRed biotechnology company, cat. No: 201-12-1303, China). The assay of BDNF was performed according to the instructions manual of the kit manufacturer and BDNF concentrations were detected spectrophotometrically using an ELISA microtiter plate reader (ELX800, BioTek Instruments, Inc, SN: 1502175). Neuroimaging study Transcranial doppler ultrasound All patients investigated with color Doppler ultrasound named ESAOTE my lab 60 with 75 and m5s transducer, the transducer created the gray scale image at a frequency between 5.0–12 MHz and Doppler at frequency 5.0 MHz the depth of the image set at 10 cm/s, sample volume set at 1 mm to 2 mm and the color sensitivity and frame rate are optimized. Velocities were used to classify subjects into one of three exclusive categories: According to Time Averaged Mean Flow (TAMmx) (Normal: TAMmx less than 170 or equal cm H2O- Conditional: TAMmx 170–199 cm H2O- High risk: TAMmx more than 200 cm H2O.10 Magnetic Resonance Imaging (MRI) High-risk TCD patients underwent MRI for detection of any radiological evidence of a stroke at the Radiology Department, Faculty of Medicine, Menoufia University using MR TOSHIBA Vantage 1.5 Tesla using NV head coil, and all patients were found normal. Sample size calculation According to Lance et al.11 at power 80% and CI 95%, sample size was calculated and found to be 40 subjects in each group with case to control ratio 1:1. Statistical analysis Data were analyzed using IBM SPSS statistics version 20 (SPSS Inc., Chicago, IL). Chi-square test was used to examine relationship between qualitative variables. For quantitative data, Student t-test was used to compare two groups. Kruskal–Wallis test was used to analyze more than two groups as appropriate. The receiver operator characteristic (ROC) curve graphically represents relationship between sensitivity and specificity at different cut-off points for BDNF. Multiple linear regression was carried out to investigate relationship between the dependent variable BDNF and independent variables. A p-value < 0.05 was considered significant. Results Socio-demographic data of the studied groups were reported in (Table 1). There was a statistical significant difference between both groups regarding the consanguinity (p < 0.001). Regarding the laboratory findings, there was a significant decrease in both hemoglobin level and hematocrit. There was a significant increase in white blood cell count, platelet count, serum ferritin, and BDNF as in (Table 2).Table 1 Socio-demographic data of studied groups. Variables Case No = 40 Control No = 40 Test of sig. P value Age (Years)  Mean ± SD 9.86 ± 4.74 9.43 ± 4.16 t p = 0.689  Range 2–18 2–18 0.402  Median 9 9 Sex χ2 Male 22 (55%) 21 (52.5%) p = 1.0 Female 18 (45%) 19 (47.5%) 0.0 Consanguinity χ2 Yes 21 (52.5%) 5 (12.5%) p < 0.001 No 19 (47.5%) 35 (87.5%) 15.664 Weight (Kg) t Mean ± SD 29.04 ± 13.38 30 ± 12 p = 0.8 Range 11–58 14–60 0.51 Median 25 37.5 Height (cm) t Mean ± SD 128 ± 24 145 ± 22 p = 0.965 Range 85–176 100–175 −0.4 Median 122 123 BMI (Kg/m2) t Mean ± SD 17.09 ± 2.61 17.55 ± 2.46 P = 0.7 Range 12.25–24 13–26 0.5 Median 16.8 18 SCD patients No. % Sickle cell anemia 22 55 ---------------- ---------- --------- Sickle thalassemia 18 45 SD standard deviation, t student’s t test, χ2 Chi-square test, BMI Body mass index. Table 2 Comparison of the laboratory data in the two studied groups. Variables Case No = 40 Control No = 40 Test of sig. P value Hb (gm/dl)  Mean ± SD 9.2 ± 1.4 11.3 ± 1.2 t = −6.668 p < 0.001*  Median (Min–Max) 9.1 (6.3–11.2) 11.2 (11.5–13.0) Hct (%)  Mean ± SD 27.3 ± 4.5 32.0 ± 4.5 t = −4.387 p < 0.001*  Median (Min–Max) 26.6 (18.5–34.7) 33.0 (22.9–37.6) MCV (fl)  Mean ± SD 75.3 ± 7.9 73.2 ± 5.3 t = 1.307 p = 0.196  Median (Min–Max) 76.1 (73.4–80.3) 73.5 (70–79.9) MCH (Pg)  Mean ± SD 26.5 ± 4.1 23.4 ± 2.1 t = 0.17 P = 0.92  Median (Min–Max) 26.0 (21.0–30.5) 23.2 (22.7–29.2) Platelets (×103/mm3)  Mean ± SD 352.5 ± 202.0 230.3 ± 35.8 t = 3.523 p = 0.001*  Median (Min–Max) 288 (163–758) 229 (172–286) WBCs (×103/mm3)  Mean ± SD 10.2 ± 4.9 7.8 ± 1.5 t = 2.734 p = 0.008*  Median (Min–Max) 8.6 (4.8–24.5) 7.6 (5.8–10.3) Serum ferritin (ng/ml)  Mean ± SD 933.24 ± 941 44.5 ± 22 t = 3.38 p < 0.001*  Median (Min–Max) 754 (18.1–3860) 50 (35.5–57) Serum BDNF (ng/ml)  Mean ± SD 12.83 ± 2.95 1.15 ± 0.85 t = 2.353 p = 0.002*  Median (Min–Max) 2.19–15 0.62–2.36 Hb hemoglobin, Hct hematocrit, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, WBCs white blood cells, BDNF brain-derived neurotrophic factor. An asterisk symbol “*” denotes significant p values. Transcranial Doppler (TCD) findings were normal in 9 cases, conditional in 26 cases, and high-risk in 5 cases. MRI was done for the five cases that had high risk and showed normal findings. Conditional and high risk TCD patients received blood transfusion for 3–6 months. A statically significant difference was found between patients with normal TCD versus conditional and high-risk findings regarding BDNF as shown in (Table 3).Table 3 Comparison between transcranial Doppler ultrasound among studied patients and its relation to BDNF. Variables Cases = 40 No % Transcranial Doppler  Normal (≤170 cm/s) 9 22.5  Conditional (170–199 cm/s) 26 65  High risk (>200 cm/s) 5 12.5 Variables Serum BDNF (ng/ml) P value Mean ± SD Median (Min–Max) Test of Significance Transcranial Doppler  Normal (≤ 170 cm/s) 1.36 ± 0.81 1.1 (2.19–2.36) H = 12.439 p1 = 0.037*  Conditional (170–199 cm/s) 2.47 ± 1.01 2.7 (2.84–13.77) p2 = 0.01*  High risk (>200 cm/s) 3.24 ± 0.98 3.28 (4.06–15) p3 = 1.0 H; Kruskal Wallis test, Pairwise comparison was done using Wilcoxon Ranked test. p1; p value between normal and conditional. p2; p value between normal and high risk. p3; p value between conditional and high risk. An asterisk symbol “*” denotes significant p values. ROC curve analysis of BDNF for the diagnostic and prognostic ability of BDNF to detect SCD complications with AUC = 0.702, a cut-off point of >0.69, 89.5% sensitivity, and 80% specificity (p = 0.004) as in (Table 4 and Fig. 1). Multivariate analysis revealed that abnormal TCD findings were significant for contributing to the prediction of BDNF which increased by 1.45 in patients who have abnormal TCD findings compared to patients with normal TCD findings, 95% CI (0.743 to 2.16) as in (Table 5).Table 4 The ROC curve analysis of serum BDNF for prediction of stroke in SCD patients. AUC P value (95% CI) Cut-off point Sensitivity Specificity PPV NPV Accuracy 0.702 0.004 0.577–0.822 >0.69 89.5% 80% 77.6% 90.8% 83.9 AUC Area under the curve, PPV positive predictive value, NPV negative predictive value. Fig. 1 ROC curve analysis of serum BDNF among studied patients. Table 5 Multiple linear regression analysis to predict the effect of the independent contribution of different factors on BDNF. Predictors Standardized Coefficients Beta P value 95% Confidence Interval Age (year) 0.041 0.83 (−0.08 to 0.1) SexA −0.050 0.75 (−0.8 to 0.58) HbS 0.186 0.334 (−0.157 to 0.448) Transcranial DopplerB 0.638 0.0001* (0.743 to 2.16) Dependent Variable: BDNF. A ref; female. B ref; normal Doppler. An asterisk symbol “*” denotes significant p values. Discussion Based on hematological investigations, the current study showed a highly significant difference as regards Hb, Hct, platelets, and WBCs. Serum ferritin and BDNF were increased in patients than in controls. Elevated BDNF levels were found in SCD children with both conditional and high-risk TCD compared to controls. Previous study included 70 children with SCD and 40 children as a control group reported normocytic normochromic anemia with leukocytosis and thrombocytosis in the patient group. Serum ferritin was higher in patients than in the control group.12 Lance et al.13 reported that BDNF levels were significantly higher in children with SCD in comparison to healthy children. Chambliss et al.14 illustrated that BDNF levels were elevated 3 fold in SCD children compared to healthy controls. Certain studies illustrated the association between elevated serum BDNF and ischemic and traumatic brain injury.8,15 Hyacinth et al.16 illustrated higher BDNF levels in SATCD (SCA with abnormal TCD compared with SNTCD (SCA with normal TCD) and controls. Also, serum BDNF level was higher in SNTCD (SCA with normal TCD) than in controls. Higher serum levels of BDNF have been associated with high TCD velocity in children with SCD. Also, BDNF was positively correlated with the volume of the infarction, so it is involved in the pathophysiology of cerebrovascular disease in SCD.17 Elevated BDNF level in children with SCA is an adaptive/protective response to reduce cell death during periods of cerebral ischemia caused by abnormal cerebral blood flow (CBF).18,19 Based on TCD findings in this study, 9 SCD patients had normal findings, 26 of them had conditional findings and 5 had high-risk TCD. Sabarense et al.20 found 45 SCD patients with high-risk TCD. Only two of them had a stroke. In France, 92 SCD children had abnormal TCD and no patient had a stroke.21 In the US, 88 SCD children study, 46 children had normal TCD, 17 children had conditional TCD and 19 children had high-risk TCD and none of them had a stroke.22 A Brazilian study reported 15 patients with abnormal TCD under chronic transfusion for primary prevention of stroke.23 ROC curve analysis of BDNF for the diagnostic and prognostic ability of BDNF to detect SCD complications with AUC = 0.702, a cut-off point of 0.802, 89.5% sensitivity, and 80% specificity. Multiple linear regression analysis revealed that abnormal TCD is significant for contributing to the prediction of BDNF which increased by 1.45 in patients who have abnormal TCD compared to patients with normal TCD, 95% CI (0.743 to 2.16). The ROC curve analysis of BDNF was sensitive (AUC = 0.8) and considered a good predictor of abnormal CBF velocity as indicated by high TCD velocity measurement. Logistic regression modeling showed that elevated BDNF level was significantly associated with increased odds of having abnormally high CBF velocity.16 The limitation of our study was small sample size, but this is explained by decreased number of patients who had sickle cell disease in our country. Conclusion BDNF levels increased in SCD patients with conditional and high-risk TCD. So, BDNF may be a potential biomarker for stroke risk prediction in patients unable to receive TCD. Acknowledgements The authors would like to express their gratitude to all participants. This research did not receive any fund. Author contributions Conceptualization, A.A.M., N.M.S.A.E.H.; Formal analysis, A.A.M., N.M.S.A.E.H., S.A.A.E.N., A.S.A. and M.S.R.; Funding acquisition, A.A.M., N.M.S.A.E.H., S.A.A.E.N., A.S.A. and M.S.R.; Investigation, A.A.M., N.M.S.A.E.H. Methodology, A.A.M., and A.S.A.; Resources, A.A.M., N.M.S.A.E.H., S.A.A.E.N., A.S.A.; Supervision, A.A.M., N.M.S.A.E.H., S.A.A.E.N., A.S.A. and M.S.R.; Writing—review & editing, A.A.M., and A.S.A. All authors have read and agreed to the published version of the manuscript. Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Competing interests The authors declare no competing interests. Ethical approval The Institutional Review Board (IRB) of the Menoufia Faculty of Medicine approved the study (ID: 10/2020 PEDI 12). Research work was performed in accordance with the Declaration of Helsinki. Informed consent Informed consent was obtained from the parents of the participants. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. Hoppe C Neumayr L Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics under Development Hematol. Oncol. Clin. North Am. 2019 33 355 371 10.1016/j.hoc.2019.01.014 31030807 2. Galadanci AA DeBaun NR Galadanci NA Neurologic complications in children under five years with sickle cell disease Neurosci. Lett. 2019 706 201 206 10.1016/j.neulet.2019.04.030 31039424 3. Aster, J. C. Disease of organs systems: Red blood cells and bleeding disorders – sickle cell disease. In: Robins and Cotranʼs Pathologic basis of disease. (eds. Vinay, K., Fausto, N. & Abbas, A. K.) 7 Ed. 628–632 (Elsevier Saunders, Philadelphia, 2005). 4. Wood DH Cerebrovascular complications of sickle cell anemia Stroke 1978 9 73 75 10.1161/01.STR.9.1.73 622748 5. Yalçin H Sickle cell disease with regional silent cerebral infarction detected by SPECT Clin. Nucl. Med 2007 32 842 843 10.1097/RLU.0b013e318156bb11 18075416 6. Gudasheva TA Povarnina PY Tarasiuk AV Seredenin SB Low‐molecular mimetics of nerve growth factor and brain‐derived neurotrophic factor: Design and pharmacological properties Med. Res. Rev. 2021 41 2746 2774 10.1002/med.21721 32808322 7. Angelova A Angelov B Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair Neural Regen. Res. 2017 12 886 889 10.4103/1673-5374.208546 28761415 8. Korley FK Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury J. Neurotrauma 2016 33 215 225 10.1089/neu.2015.3949 26159676 9. Naegelin Y Measuring and validating the levels of brain-derived neurotrophic factor in human serum Eneuro 2018 5 10 15 10.1523/ENEURO.0419-17.2018 10. Buchanan I James-Herry A Osunkwo I The other side of abnormal: a case series of low transcranial Doppler velocities associated with stroke in children with sickle cell disease J. Pediatr. Hematol./Oncol. 2013 35 543 546 10.1097/MPH.0b013e318279caae 23211694 11. Lance EI Casella JF Everett AD Barron‐Casella E Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease PROTEOMICS–Clin. Appl. 2014 8 813 827 10.1002/prca.201400069 25290359 12. El-Gamasy MA El-Naghy WS Early predictors of renal dysfunction in pediatric patients with sickle cell disease Indian J. Nephrol. 2019 29 28 33 30814790 13. Lance EI Barron‐Casella E Everett AD Casella JF Brain‐derived neurotrophic factor levels in pediatric sickle cell disease Pediatr. Blood cancer 2020 67 e28076 10.1002/pbc.28076 31736231 14. Chambliss C Elevated neuregulin-1 βlevels correlate with plasma biomarkers of cerebral injury and high stroke risk in children with sickle cell anemia Endocr. Metab. Sci. 2021 3 100088 10.1016/j.endmts.2021.100088 35935682 15. Chen A Xiong LJ Tong Y Mao M The neuroprotective roles of BDNF in hypoxic ischemic brain injury Biomed. Rep. 2013 1 167 176 10.3892/br.2012.48 24648914 16. Hyacinth HI Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia Cytokine 2012 60 302 308 10.1016/j.cyto.2012.05.017 22704695 17. Drexelius JA Kanne CK Tran HD Hyacinth HI Sheehan VA Plasma BDNF Levels Are Associated with Stroke in Children with SCD Blood 2019 134 3565 10.1182/blood-2019-131191 18. Schäbitz WR Intravenous brain derived neurotrophic factor reduces infarct size and counter regulates Bax and Bcl-2 expression after temporary focal cerebral ischemia Stroke 2000 31 2212 2217 10.1161/01.STR.31.9.2212 10978054 19. Ferrer I Brain derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat Acta Neuropathol. 2001 101 229 238 10.1007/s004010000268 11307622 20. Sabarense AP Silva CM de Sousa Rodrigues Muniz MB Viana MB Follow-up of children with sickle cell anemia screened with transcranial Doppler and enrolled in a primary prevention program of ischemic stroke Hematol. Transfus. Cell Ther. 2022 44 478 484 10.1016/j.htct.2021.05.001 34210619 21. Bernaudin F Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities Blood 2016 127 1814 1822 10.1182/blood-2015-10-675231 26851292 22. Kwiatkowski JL Yim E Miller S Adams RJ STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease Pediatr. Blood Cancer 2011 56 777 782 10.1002/pbc.22951 21370410 23. Franco JM Chronic transfusion therapy effectiveness as primary stroke prophylaxis in sickle cell disease patients Hematol. Transfus. Cell Ther. 2020 42 12 17 10.1016/j.htct.2018.05.015 31791880